▎WuXiEdited by Kant Content Team

GSK announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) achieved positive results in a pre-specified interim analysis of the Phase 3 clinical trial DREAMM-7. The trial evaluated the efficacy of Blenrep in combination with bortezomib and dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma.The trial met the key secondary endpoint of overall survival (OS), showing that Blenrep in combination with BorDex significantly reduced the risk of death compared to the standard treatment regimen.Interim analysis results, including safety data, will be presented at the upcoming 66th American Society of Hematology (ASH) Annual Meeting.

In the DREAMM-7 study, patients received treatment with Blenrep in combination with BorDex, or daratumumab plus BorDex. Previously announcedClinical Trial DataShow,The median progression-free survival (PFS) for patients receiving Blenrep combination therapy (N=243) was 36.6 months (95% CI: 28.4-NR), nearly two years longer than the 13.4 months (95% CI: 11.1-17.5) observed in the active comparator group (N=251)., the risk of disease progression or death in patients receiving Blenrep combination therapy was reduced by nearly 60% (HR: 0.41, 95% CI: 0.31-0.53, p<0.00001), achieving the primary endpoint of this trial.

The DREAMM clinical development program will continue to evaluate the potential of Blenrep in treating earlier-stage patients and its combination with innovative therapies and standard treatment regimens. In addition to DREAMM-7, the program also includes the ongoing Phase 3 clinical trial DREAMM-8, which assesses the efficacy of Blenrep in combination with pomalidomide and dexamethasone versus bortezomib combined with pomalidomide and dexamethasone. As part of the DREAMM program, GSK is expected to initiate a Phase 3 study by the end of 2024 for newly diagnosed multiple myeloma patients who are ineligible for hematopoietic stem cell transplantation.

Blenrep is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), consisting of a humanized anti-BCMA monoclonal antibody linked to the cytotoxic payload auristatin F through a non-cleavable linker.In 2024, based on the results of the DREAMM-7 and DREAMM-8 trials, the Blenrep combination therapy has been submitted for marketing approval in the United States, the European Union, Japan, the United Kingdom, Canada, and Switzerland for the treatment of relapsed or refractory multiple myeloma.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biomedicine and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized reproduction by media or institutions in any form on other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain the reprint guidelines.